Author(s) Bansi Nagji, CEO, PANTHERx Rare
Bansi Nagji discusses the shifting science behind rare and orphan drug development, including what it takes for therapies to succeed well beyond launch.
Key Takeaways
- Understand why scientific innovation targets rare and orphan disease treatments
- Learn what distinguishes a rare-only pharmacy model from traditional specialty pharmacy approaches
- Recognize why launch is only the starting point for long-term therapy success